Thursday, January 23, 2020 9:43:31 PM
ziploc I'm not going to bash you but I do want to note that other companies with inferior medicines for the same general indication charge an ABSOLUTE FORTUNE for their garbage and make no apologies.
Captalism should have a heart, but a company with an innovation of this magnitude, and investors to reward for their steadfast risk-taking, has to balance affordability with return on investment. Otherwise innovation dies the old-fashioned way -- meaning, the European way.
You've read the ICER reports and other measures of cost/benefit, I'm sure. It's a rare drug that has the cost/benefit profile of Vascepa. It rocks the status quo, and all the Big Pharma competitors hate it, and the cockroaches will do anything to stop its progress, and to accuse AMRN of profiteering on Vascepa is incredibly unfair.
Vascepa is priced for the masses already. If insurance carriers decide to arbitrarily create barriers to affordability while kissing the asses of their bigger Pharma partners, that isn't AMRN's fault. Over time, the efficacy of the drug will steamroll all the political bullshit.
AMRN isn't required to be the bagholder for redressing Big Pharma greed. AMRN/Vascepa is the pattern buster when it comes to Big Pharma soaking the poor for small incremental health benefits.
Captalism should have a heart, but a company with an innovation of this magnitude, and investors to reward for their steadfast risk-taking, has to balance affordability with return on investment. Otherwise innovation dies the old-fashioned way -- meaning, the European way.
You've read the ICER reports and other measures of cost/benefit, I'm sure. It's a rare drug that has the cost/benefit profile of Vascepa. It rocks the status quo, and all the Big Pharma competitors hate it, and the cockroaches will do anything to stop its progress, and to accuse AMRN of profiteering on Vascepa is incredibly unfair.
Vascepa is priced for the masses already. If insurance carriers decide to arbitrarily create barriers to affordability while kissing the asses of their bigger Pharma partners, that isn't AMRN's fault. Over time, the efficacy of the drug will steamroll all the political bullshit.
AMRN isn't required to be the bagholder for redressing Big Pharma greed. AMRN/Vascepa is the pattern buster when it comes to Big Pharma soaking the poor for small incremental health benefits.
“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
